Hal Barron, GSK R&D chief (GSK via investor day livestream)
July 29, 2021 10:10 AM EDTUpdated 11:07 AM
R&D

What made Glax­o­SmithK­line’s Hal Bar­ron spend $2.2B to get back in­to neu­ro? Alec­tor flash­es the da­ta

Jason Mast

Editor

What made GSK’s Hal Bar­ron spend $700 mil­lion cash to get in on a pair of an­ti­bod­ies for neu­rode­gen­er­a­tion?

Alec­tor flashed part of the an­swer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA meet­ing to pick next win­ter's flu shot is can­celed, in omi­nous sign for US vac­cine pol­i­cy

Up­dat­ed: Lil­ly joins Trump ad­min­is­tra­tion to an­nounce $27B man­u­fac­tur­ing com­mit­ment

As­traZeneca’s SERD hits pri­ma­ry end­point in late-stage tri­al, but first-line po­ten­tial re­mains un­cer­tain

Af­ter re­jec­tion, Re­gen­eron seeks ac­cel­er­at­ed ap­proval of bis­pe­cif­ic for on­ly one of two types of lym­phoma

Re­gen­eron, two Chi­nese biotechs tout promise of their hear­ing loss gene ther­a­pies

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times